Taking people in JapanNo phase
Observes brexpiprazole safety in people with Alzheimer's dementia
Studies safety of brexpiprazole in people with Alzheimer's dementia and agitation.
Plain-language title generated from the registry record
Registry title: REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia
Key facts
- Where
- Osaka, JapanSee the site
Where in Japan
- Pharmacovigilance DepartmentOsaka, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Otsuka Pharmaceutical Co., Ltd.
- Trial code
- NCT06875986
- Record updated
- 20 October 2026
- Original description
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.Read full original descriptionShow less
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
Inclusion: Patients diagnosed with Alzheimer's disease.
Exclusion: -.